| Cite this article: |
| CHEN Shuai,LIANG Yanwen,LIN Jiansuo,SUN Junyu,REN Jianwei,LIU Yi.The impact of LAG3 splice variants on hepatocellular carcinoma cell proliferat-ion and sorafenib resistance[J].Journal Of Pharmaceutical Research,2026,45(1):17-21,95[Click to copy] |
|
| 摘要: |
| 目的 构建在肝癌细胞表达的免疫活化基因3(LAG3)剪接变异体稳转细胞株,探讨剪接变异体对肝癌细胞增殖及对索拉非尼耐药性的影响。方法 以Hep3B cDNA为模板,采用巢式PCR扩增LAG3基因,对琼脂糖凝胶电泳分离差异条带测序并与NCBI数据库中的LAG3转录变体对比,发现其相对人全长LAG3 mRNA缺少3号外显子(LAG3Δ3)。构建LAG3Δ3-pIGvetor重组质粒,通过慢病毒系统将重组质粒转染至Hep3B细胞,嘌呤霉素筛选后,利用RT-qPCR和Western blotting验证稳转细胞是否构建成功,MTT法评估细胞增殖及耐药性。结果 筛选后的Hep3B-LAG3Δ3细胞LAG3Δ3 mRNA及蛋白水平较对照Hep3B-NC细胞显著增高(P<0.000 1)。过表达LAG3Δ3细胞的增殖能力更强,其对索拉非尼的耐药性相比Hep3B-NC细胞有所增强(P<0.05)。结论 成功构建Hep3B-LAG3Δ3剪接变异体稳转细胞株,LAG3Δ3可促进肝癌细胞增殖,减弱肝癌细胞对索拉非尼的敏感性。 |
| 关键词: 淋巴细胞活化因子3 剪接变异体 稳转细胞 耐药 索拉非尼 |
| DOI:10.13506/j.cnki.jpr.2026.01.003 |
| 基金项目: |
|
Publication Date:January 26, 2026
|
|
| The impact of LAG3 splice variants on hepatocellular carcinoma cell proliferat-ion and sorafenib resistance |
| CHEN Shuai1,LIANG Yanwen1,LIN Jiansuo2,SUN Junyu3,REN Jianwei4,LIU Yi1 |
| (1.School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang, 524023, China
2. School of Basic Medical Sciences, Guangdong Medical University, Dongguan 523808, China
3. School of Pharmacy, Guangdong Medical University, Dongguan 523808, China
4. Shenzhen Reke Biotechnology Co., LTD., Shenzhen, 518100, China) |
| Abstract: |
| Objective Objective To construct a stable cell line expressing splice variants of immune activation gene 3 (LAG3) in hepatocellular carcinoma cells and to investigate the effects of splice variants on the proliferation of hepatocellular carcinoma cells and sorafenib resistance.Methods Hep3B cDNA was used as a template to amplify the LAG3 gene by nested PCR. The differential bands separated by agarose gel electrophoresis were sequenced and compared with the LAG3 transcript variants in the NCBI database. It was found that it lacked exon 3 (LAG3Δ3) relative to the full-length human LAG3 mRNA. The LAG3Δ3-pIGvetor recombinant plasmid was constructed and transfected into Hep3B cells by lentiviral system. After puromycin selection, RT-qPCR and Western blotting were used to verify whether the stable cell line was successfully constructed. The cell proliferation and drug resistance were evaluated by MTT method. Results The levels of LAG3Δ3 mRNA and protein in the selected Hep3B-LAG3Δ3 cells were significantly increased compared with those in the control Hep3B-NC cells (P<0.000 1). The proliferation ability of cells overexpressing LAG3Δ3 was stronger and their resistance to sorafenib was enhanced compared with Hep3B-NC cells (P<0.05).Conclusion Hep3B-LAG3Δ3 splicing variant stable cell line was successfully constructed. LAG3Δ3 can promote the proliferation of liver cancer cells and reduce the sensitivity of liver cancer cells to sorafenib. |
| Key words: Lymphocyte activation gene 3 Splice variant Stable transfection Drug resistance |